Inclusion Criteria:  Male or female over 18 years of age, Patient candidate for a first transplant or a re-transplantation, registered on the national waiting list of the Biomedicine Agency. CMV seropositive patients (positive serology at pre-transplant assessment or at D0 of transplantation) Patients receiving a kidney transplant from a deceased or living donor. Women of childbearing age with a negative pregnancy test at inclusion and agreeing to the use of effective contraception throughout the study period and two months after the end of the follow-up period. Patient affiliated to or benefiting from a social security scheme.  Exclusion Criteria:  CMV negative (R-) patients. Historical or current Graft Incompatible Rate (GIR) > 85%. Patients who have received anti-CMV therapy within 28 days prior to transplantation. Indication for induction therapy with anti-lymphocyte globulin, rituximab, polyvalent intravenous immunoglobulin or any other immunomodulatory molecule, and mTOR inhibitor therapy, which have been described to be associated with a decreased incidence of CMV infection Patients who have received or are receiving a solid organ transplant other than a kidney transplant. Patients known to be seropositive for human immunodeficiency virus (HIV), hepatitis B virus (HBV; HbS Ag positive) or hepatitis C virus (HCV; HCV antibody positive), Known allergy, contraindication or intolerance to specific anti-HCV Ig, mycophenolic acid, basiliximab, corticosteroids, cyclosporine A, tacrolimus or to excipients of these products. Any form of substance abuse, psychiatric disorder or condition that, in the opinion of the investigator, may complicate communication during follow-up. Foreseeable inability to comply with planned protocol visits/reviews. Patients under guardianship/guardianship Pregnant or breastfeeding woman Patients with a contraindication to receiving Cytotect